Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + sintilimab + multimodality radiotherapy
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Disitamab vedotin + sintilimab + multimodality radiotherapy is a combination therapeutic regimen being investigated for the treatment of HER2-positive advanced gastric cancer. The regimen consists of disitamab vedotin (RC48), a novel antibody-drug conjugate (ADC) targeting HER2 with a monomethyl auristatin E (MMAE) payload; sintilimab, a programmed cell death protein 1 (PD-1) monoclonal antibody; and multimodality radiotherapy (MMRT), which combines low-dose radiotherapy (LDRT) and stereotactic body radiotherapy (SBRT). The rationale for this combination is based on the potential of disitamab vedotin to modulate the tumor immune microenvironment and synergize with PD-1 blockade, while MMRT enhances systemic anti-tumor responses by releasing tumor antigens and further remodeling the immune microenvironment. This approach is specifically targeted at patients who have failed standard first- and second-line therapies.
- Other names
- RC48 + sintilimab + MMRT
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + sintilimab + multimodality radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + sintilimab + multimodality radiotherapy.